Longevity Tech Fund is a Boca Raton-based venture capital fund focused on early-stage startups and spinouts in longevity, rejuvenation biotech, AI, and related life science categories. It is thesis-led around aging as a central investment lens and has become one of the more active specialized investors in that space. Its portfolio construction reflects breadth across therapeutics, diagnostics, and platform technologies.

Within that longevity framework, the fund explicitly includes neurotechnology as an area of interest, especially where companies address neurodegeneration, cognitive decline, or brain aging. This gives it a differentiated place in the market: it is not a pure neurotech fund, but it is directly relevant to brain health within the aging context. For founders working on aging-related CNS or neurodiagnostic problems, that thematic fit can be strong.

The fund invests globally from a US base. For neurotech, it is most relevant to companies working on neurological aging, dementia, prevention, or biomarkers of brain decline. It is a useful target where the company’s story is clearly anchored in the biology and economics of aging.